CY1110612T1 - Φαρμακευτικες συνθεσεις για την παρατεταμενη απελευθερωση δραστικης ουσιας (ουσιων) καθως και οι εφαρμογες αυτων και κυριως οι θεραπευτικες - Google Patents

Φαρμακευτικες συνθεσεις για την παρατεταμενη απελευθερωση δραστικης ουσιας (ουσιων) καθως και οι εφαρμογες αυτων και κυριως οι θεραπευτικες

Info

Publication number
CY1110612T1
CY1110612T1 CY20101100228T CY101100228T CY1110612T1 CY 1110612 T1 CY1110612 T1 CY 1110612T1 CY 20101100228 T CY20101100228 T CY 20101100228T CY 101100228 T CY101100228 T CY 101100228T CY 1110612 T1 CY1110612 T1 CY 1110612T1
Authority
CY
Cyprus
Prior art keywords
release
physiological
duration
water
parenteral injection
Prior art date
Application number
CY20101100228T
Other languages
English (en)
Inventor
Gauthier Pouliquen
Olivier Soula
Rémi Meyrueix
Florence Nicolas
Original Assignee
Flamel Technologies, Société Anonyme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies, Société Anonyme filed Critical Flamel Technologies, Société Anonyme
Publication of CY1110612T1 publication Critical patent/CY1110612T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέες φαρμακευτικές συνθέσεις που βασίζονται σε ληφθέντα κολλοειδή στερεά και υγρά εναιωρήματα για την παρατεταμένη απελευθέρωση δραστικού (ων) συστατικού (ων), κατά προτίμηση πρωτεϊνικού (ων), καθώς επίσης (αφορά) και εφαρμογές, και κυρίως θεραπευτικές, των συνθέσεων αυτών. Σκοπός της εφεύρεσης είναι να προτείνει μία υγρή φαρμακευτική σύνθεση για την παρατεταμένη απελευθέρωση δραστικού (ων) συστατικού (ων), η οποία επιτρέπει, μετά από ένεση μέσω παρεντερικής οδού, να αυξηθεί σημαντικά η διάρκεια της απελευθέρωσης εν ζωή (in vivo) θεραπευτικής πρωτεΐνης, ενώ να ελαττώνεται, η υψηλή πλασματική συγκέντρωση της ενεργού πρωτεΐνης, (η υγρή φαρμακευτική σύνθεση πρέπει) να είναι, σταθερή κατά τη διατήρηση της, και επιπλέον βιοσυμβατή, μη τοξικά βιοαποικοδομήσιμη, μη παθογενής και τοπικά καλά ανεκτή. Η σύνθεση σύμφωνα με την εφεύρεση είναι ένα ληφθέν κολλοειδές εναιώρημα χαμηλού ιξώδους, με υπομικροσκοπικά τεμαχίδια βιοδιασπώμενου πολυμερούς ΡΟ, υδροδιαλυτό και φορέας υδρόφοβων ομάδων (GH), τα οποία τεμαχίδια συνδέονται κατά τρόπο μη ομοιοπολικό με τουλάχιστον ένα δραστικό συστατικό (ΡΑ) και σχηματίζει κολλοειδές πήγμα στο σημείο της ένεσης, η οποία πηκτωματοποίηση προκαλείται από πρωτεΐνη φυσιολογική.
CY20101100228T 2003-11-21 2010-03-09 Φαρμακευτικες συνθεσεις για την παρατεταμενη απελευθερωση δραστικης ουσιας (ουσιων) καθως και οι εφαρμογες αυτων και κυριως οι θεραπευτικες CY1110612T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0350887A FR2862536B1 (fr) 2003-11-21 2003-11-21 Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
EP04805846A EP1689425B8 (fr) 2003-11-21 2004-11-19 Formulations pharmaceutiques pour la libération prolongée de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques

Publications (1)

Publication Number Publication Date
CY1110612T1 true CY1110612T1 (el) 2015-04-29

Family

ID=34531384

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100228T CY1110612T1 (el) 2003-11-21 2010-03-09 Φαρμακευτικες συνθεσεις για την παρατεταμενη απελευθερωση δραστικης ουσιας (ουσιων) καθως και οι εφαρμογες αυτων και κυριως οι θεραπευτικες

Country Status (22)

Country Link
US (1) US8084045B2 (el)
EP (1) EP1689425B8 (el)
JP (1) JP4988352B2 (el)
KR (1) KR101092547B1 (el)
CN (1) CN1886151B (el)
AT (1) ATE451116T1 (el)
AU (1) AU2004292369B2 (el)
BR (1) BRPI0416779B8 (el)
CA (1) CA2546675C (el)
CY (1) CY1110612T1 (el)
DE (1) DE602004024571D1 (el)
DK (1) DK1689425T3 (el)
ES (1) ES2338012T3 (el)
FR (1) FR2862536B1 (el)
IL (1) IL175768A (el)
MX (1) MXPA06005717A (el)
PL (1) PL1689425T3 (el)
PT (1) PT1689425E (el)
SI (1) SI1689425T1 (el)
TW (1) TW200518775A (el)
WO (1) WO2005051416A1 (el)
ZA (1) ZA200603950B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
WO2004082718A1 (ja) * 2003-03-20 2004-09-30 Nippon Kayaku Kabushiki Kaisha 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
BRPI0515573A (pt) * 2004-09-22 2008-07-29 Nippon Kayaku Kk copolìmero por blocos, preparação de micela e agente anticáncer contendo a mesma como o ingrediente ativo
DE102005028080A1 (de) * 2005-06-17 2006-12-21 Bayer Technology Services Gmbh Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol
JP5249016B2 (ja) * 2006-03-28 2013-07-31 日本化薬株式会社 タキサン類の高分子結合体
JP5181347B2 (ja) 2006-05-18 2013-04-10 日本化薬株式会社 ポドフィロトキシン類の高分子結合体
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
WO2008056596A1 (en) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
FR2915683B1 (fr) 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
FR2915684B1 (fr) * 2007-05-03 2011-01-14 Flamel Tech Sa Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
JP5584132B2 (ja) * 2007-11-15 2014-09-03 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 疼痛の治療のための前立腺酸性ホスファターゼ
EP2258397B1 (en) * 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
US20100021549A1 (en) * 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
FR2940619B1 (fr) 2008-12-31 2012-02-10 Flamel Technologies Sa Composition comprenant un actif de solubilite aqueuse faible ou moyenne
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
CN102421827B (zh) * 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
JP4829351B2 (ja) * 2010-02-05 2011-12-07 ナノキャリア株式会社 易崩壊型ポリマーミセル組成物
CN101893619B (zh) * 2010-02-10 2013-11-13 上海蓝怡科技有限公司 改进乳胶悬浊液稳定性的方法
TWI448485B (zh) * 2010-08-03 2014-08-11 Univ Nat Taiwan Normal 半互穿網絡型水膠聚合物、其製造方法及包含其之水泥組成物
TW201304805A (zh) 2010-11-17 2013-02-01 Nippon Kayaku Kk 新穎之胞核苷系代謝拮抗劑之高分子衍生物
US9335195B2 (en) * 2011-02-16 2016-05-10 Baker Hughes Incorporated Multiphase meter to provide data for production management
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
CA2847114C (en) 2011-09-11 2018-08-21 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
WO2015032971A1 (en) * 2013-09-09 2015-03-12 Lek Pharmaceuticals D.D. Polymer selection for preparation of nps with high protein loading
US10037359B2 (en) * 2016-05-23 2018-07-31 Microsoft Technology Licensing, Llc Search results using social routing of content
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
AU2020231916A1 (en) 2019-03-01 2021-08-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN114469803B (zh) * 2022-01-26 2024-03-19 乐彩华年(广州)电子商务有限公司 一种超分子组合物及其制备方法与应用
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
DE1189636B (de) 1959-12-28 1965-03-25 Licentia Gmbh UEberspannungsableiter erniedrigter Bauhoehe mit Loeschfunkenstrecke und spannungsabhaengigen Widerstaenden
GB1024393A (en) 1963-03-30 1966-03-30 Asahi Chemical Ind Process for polymerizing n-carboxy-ª‡-amino acid anhydrides
FR1603159A (el) 1967-07-20 1971-03-22
US3536672A (en) 1968-10-04 1970-10-27 Kyowa Hakko Kogyo Kk Process for the polymerization of alpha-amino acid - n - carboxy anhydrides using imidazole initiators
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
FR2313915A1 (fr) 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
US4126628A (en) 1977-03-28 1978-11-21 Canadian Patents And Development Limited Acylation of amino acids
US4342739A (en) 1979-01-09 1982-08-03 Fuji Photo Film Co., Ltd. Novel material for immunological assay of biochemical components and a process for the determination of said components
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
FR2533209B1 (fr) 1982-09-22 1985-11-08 Centre Nat Rech Scient Lipopeptides, leur obtention et leur application comme emulsifiants
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
ATE60340T1 (de) 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
US4661345A (en) 1985-02-26 1987-04-28 The Rockefeller University Method for treating pertussis
EP0198769A3 (en) 1985-04-12 1987-09-02 Forest Laboratories, Inc. Floating sustained release therapeutic compositions
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
CH667874A5 (fr) 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4835293A (en) 1987-02-24 1989-05-30 E. I. Du Pont De Nemours And Company Atmospheric pressure process for preparing pure cyclic esters
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
IT1227899B (it) 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
US4976968A (en) 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
CA1340681C (en) 1989-07-07 1999-07-27 Robert Deziel Antiherpes tetrapeptides having a substituted aspartic acid side chain
IT1256651B (it) 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
GB2240547A (en) 1990-01-31 1991-08-07 Ciba Geigy Ag New compositions
US5023349A (en) 1990-05-08 1991-06-11 E. I. Du Pont De Nemours And Company Continuous process for rapid conversion of oligomers to cyclic esters
SE9002684D0 (sv) 1990-08-17 1990-08-17 Malvac Foundation C O Peter Pe New peptides and their use
FI922107A0 (fi) 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition och foerfarande.
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
FR2692263B1 (fr) 1992-06-15 1994-09-23 Flamel Tech Sa Procédé de préparation d'esters cycliques d'acides-alpha-hydroxycarboxyliques.
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
EP0674506B1 (en) 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
CA2163225A1 (en) 1993-05-20 1994-12-08 Gregory John Russell-Jones Lhrh antagonists
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
FR2708932B1 (fr) 1993-08-10 1995-11-10 Flamel Tech Sa Procédé de préparation de polyaminoacides.
KR0141431B1 (ko) 1994-05-17 1998-07-01 김상웅 생분해성 하이드로겔 고분자
JP3460340B2 (ja) 1994-09-09 2003-10-27 Ｊｓｒ株式会社 ポリ−α−アミノ酸のエマルジョンおよびその製造方法並びにポリ−α−アミノ酸の中空ポリマー粒子
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US5939485A (en) 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
FR2738835B1 (fr) 1995-09-18 1997-10-17 Oreal Composition epaissie en milieu aqueux, procede d'epaississement d'un milieu aqueux et utilisations en cosmetique
US5872210A (en) 1995-10-05 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Transframe peptide inhibitor of viral protease
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6083484A (en) 1996-10-17 2000-07-04 Molecular Biosystems, Inc. Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents
US5981761A (en) 1997-03-27 1999-11-09 Solutia Inc. Crosslinked polyaspartate salts a process for their production
KR100195291B1 (ko) 1997-07-12 1999-06-15 서경배 비이온성 비타민
US5933269A (en) * 1997-08-22 1999-08-03 Lucent Technologies Inc. Common-lens reflective magneto-optical switch
AU736812B2 (en) * 1997-10-03 2001-08-02 Btg International Limited Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
WO1999040436A1 (en) 1998-02-10 1999-08-12 University Of Utah Research Foundation METHODS FOR PURIFYING AND ASSAYING A CONUS η-CARBOXYLASE
EP0963758A3 (en) 1998-05-07 2000-03-22 Universiteit Gent Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
DE19822600C2 (de) 1998-05-20 2003-08-21 Goldschmidt Ag Th Copolymere, hydrophob modifizierte Polyasparaginsäureester mit erhöhter Molekularmasse
GB9811059D0 (en) 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
FR2801226B1 (fr) * 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
JP4585114B2 (ja) 2000-12-27 2010-11-24 三井化学株式会社 重合体及びその製造方法
JP4775985B2 (ja) 2000-12-27 2011-09-21 三井化学株式会社 重合体及びその製造方法
CA2438692C (en) 2001-02-28 2010-04-27 Akzo Nobel Nv Injectable water-in-oil emulsions
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
CA2444569C (en) 2001-04-18 2011-01-04 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
RU2197586C1 (ru) * 2001-07-25 2003-01-27 Гунгер Юрий Робертович Опорная конструкция для линии электропередачи
CN1538985A (zh) 2001-08-03 2004-10-20 用于洗涤剂组合物中的聚天冬氨酸衍生物
WO2003041689A1 (en) 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
FR2838964B1 (fr) * 2002-04-26 2004-07-09 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et leur mode de preparation
JP2003327693A (ja) 2002-05-15 2003-11-19 Mitsuru Akashi 親−疎水性修飾ポリ（γ−グルタミン酸）
TW200406386A (en) 2002-06-07 2004-05-01 Novartis Ag Organic compounds
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
DE60321816D1 (de) * 2002-12-04 2008-08-07 Flamel Tech Sa Polyaminosäuren, funktionalisiert durch mindestens eine (oligo-)aminosäure und ihre, insbesondere therapeutische, anwendung
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2860516B1 (fr) 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
FR2862535B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862541B1 (fr) 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2873040B1 (fr) 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
FR2881140B1 (fr) 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
KR20090013179A (ko) 2006-04-07 2009-02-04 아도시아 이관능화된 다당류
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
US20080102128A1 (en) 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques

Also Published As

Publication number Publication date
KR20060130076A (ko) 2006-12-18
SI1689425T1 (sl) 2010-04-30
ES2338012T3 (es) 2010-05-03
EP1689425A1 (fr) 2006-08-16
US20070196497A1 (en) 2007-08-23
MXPA06005717A (es) 2007-01-30
ATE451116T1 (de) 2009-12-15
FR2862536A1 (fr) 2005-05-27
BRPI0416779B1 (pt) 2017-01-17
CN1886151A (zh) 2006-12-27
US8084045B2 (en) 2011-12-27
JP4988352B2 (ja) 2012-08-01
CN1886151B (zh) 2012-08-29
EP1689425B8 (fr) 2010-02-17
PT1689425E (pt) 2010-04-05
KR101092547B1 (ko) 2011-12-09
ZA200603950B (en) 2008-01-08
IL175768A (en) 2012-06-28
AU2004292369A1 (en) 2005-06-09
FR2862536B1 (fr) 2007-11-23
BRPI0416779B8 (pt) 2021-05-25
EP1689425B1 (fr) 2009-12-09
AU2004292369B2 (en) 2010-12-09
DK1689425T3 (da) 2010-04-19
CA2546675C (fr) 2014-01-07
BRPI0416779A (pt) 2007-03-06
CA2546675A1 (fr) 2005-06-09
JP2007511586A (ja) 2007-05-10
WO2005051416A1 (fr) 2005-06-09
DE602004024571D1 (de) 2010-01-21
PL1689425T3 (pl) 2010-07-30
IL175768A0 (en) 2006-09-05
TW200518775A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CY1110612T1 (el) Φαρμακευτικες συνθεσεις για την παρατεταμενη απελευθερωση δραστικης ουσιας (ουσιων) καθως και οι εφαρμογες αυτων και κυριως οι θεραπευτικες
CY1110106T1 (el) Φαρμακοτεχνικες μορφες για την παρατεταμενη απελευθερωση ιντερφερονων και θεραπευτικες εφαρμογες αυτων
IL175543A (en) Liquid pharmaceutical formulations for prolonged release of interleukin(s), process for their preparation and derived product comprising submicron particles containing such formulations
BR0204804A (pt) Agente estabilizante de proteìnas para a estabilização de um material protéico em meio ácido aquoso, composição para suspensão em um lìquido ácido aquoso, método de estabilização de proteìnas em um lìquido ácido aquoso e método de formação de uma suspensão estável de material protéico em sucos ácidos
JP2005527470A5 (el)
ATE413812T1 (de) Hochlösliches sojaprotein von hohem molekulargewicht
ATE217526T1 (de) Trockene zusammensetzungen zur herstellung von emulsionen im submikron-bereich
ATE225822T1 (de) Polyionische hydrogele auf der basis von chitosan und xanthangummi zur stabilisierung und kontrollierter freisetzung von vitaminen
HU9302893D0 (en) Macromolecule-extract with bacterium, method for producing it and pharmaceutical products containing it
US20040258731A1 (en) Preparation approriate for cartilage tissue formation
CN107693842A (zh) 一种医用耐水凝胶及其制备方法
JPH07103014B2 (ja) 潤滑剤
TH101604B (th) สูตรผสมยาสำหรับการปลดปล่อยอินเตอร์เฟียรอนแบบยืดออกไปและการใช้ประโยชน์เพื่อรักษาโรค
TH101604A (th) สูตรผสมยาสำหรับการปลดปล่อยอินเตอร์เฟียรอนแบบยืดออกไปและการใช้ประโยชน์เพื่อรักษาโรค